A carregar...
Molecular characterization of HLA class II binding to the LAG‐3 T cell co‐inhibitory receptor
Immune checkpoint inhibitors (antibodies that block the T cell co‐inhibitory receptors PD‐1/PD‐L1 or CTLA‐4) have revolutionized the treatment of some forms of cancer. Importantly, combination approaches using drugs that target both pathways have been shown to boost the efficacy of such treatments....
Na minha lista:
| Publicado no: | Eur J Immunol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8101287/ https://ncbi.nlm.nih.gov/pubmed/32920841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/eji.202048753 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|